- Home
- AENT vs YMAB Comparison
AENT vs YMAB Comparison
Compare AENT & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- YMAB
- Stock Information
- Founded
- AENT 1990
- YMAB 2015
- Country
- AENT United States
- YMAB United States
- Employees
- AENT N/A
- YMAB N/A
- Industry
- AENT Durable Goods
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- YMAB Health Care
- Exchange
- AENT Nasdaq
- YMAB Nasdaq
- Market Cap
- AENT 290.3M
- YMAB 270.5M
- IPO Year
- AENT N/A
- YMAB 2018
- Fundamental
- Price
- AENT $3.61
- YMAB $4.90
- Analyst Decision
- AENT
- YMAB Buy
- Analyst Count
- AENT 0
- YMAB 11
- Target Price
- AENT N/A
- YMAB $19.64
- AVG Volume (30 Days)
- AENT 70.7K
- YMAB 333.1K
- Earning Date
- AENT 05-08-2025
- YMAB 03-04-2025
- Dividend Yield
- AENT N/A
- YMAB N/A
- EPS Growth
- AENT N/A
- YMAB N/A
- EPS
- AENT 0.13
- YMAB N/A
- Revenue
- AENT $1,070,804,000.00
- YMAB $87,685,000.00
- Revenue This Year
- AENT $4.77
- YMAB $20.07
- Revenue Next Year
- AENT N/A
- YMAB $8.76
- P/E Ratio
- AENT $28.22
- YMAB N/A
- Revenue Growth
- AENT N/A
- YMAB 3.38
- 52 Week Low
- AENT $1.10
- YMAB $4.25
- 52 Week High
- AENT $11.57
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- AENT 40.47
- YMAB 40.52
- Support Level
- AENT $3.17
- YMAB $4.45
- Resistance Level
- AENT $3.85
- YMAB $5.03
- Average True Range (ATR)
- AENT 0.43
- YMAB 0.39
- MACD
- AENT 0.04
- YMAB 0.02
- Stochastic Oscillator
- AENT 30.16
- YMAB 48.15
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.